ReNeuron Group PLC
LSE:RENE
ReNeuron Group PLC
ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. The company is headquartered in Bridgend, Glamorgan and currently employs 43 full-time employees. The company went IPO on 2005-08-12. The firm develops allogeneic stem cell technology platforms, stem cell derived exosomes and induced pluripotent stem cells. The firm's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). The firm's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. The company is engaged in Phase II clinical trial of CTX cells for stroke disability. The company is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. The company is engaged in Phase I clinical trial of hRPC stem cell candidate.
ReNeuron Group Plc engages in the development of novel cell based therapies that target significant areas of unmet medical need. The company is headquartered in Bridgend, Glamorgan and currently employs 43 full-time employees. The company went IPO on 2005-08-12. The firm develops allogeneic stem cell technology platforms, stem cell derived exosomes and induced pluripotent stem cells. The firm's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). The firm's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. The company is engaged in Phase II clinical trial of CTX cells for stroke disability. The company is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. The company is engaged in Phase I clinical trial of hRPC stem cell candidate.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
